On October 25^th, every major player in the antibody-drug conjugate field descended on San Francisco to participate in the most essential meeting of their year.

Hear what attendees had to say about this year's meeting:

“The ADC Forum exceeded my expectations. Access to cutting edge developments and interaction between the attendees were all top notch! I will attend in 2012”.
Igenica, Inc.

Great meeting. I have been working in this field for over 10 years, this meeting brings the best scientists with state of the art experience. Finally a meeting where we can focus on just ADC. Great job”.
Bristol Myers Squibb

“ADC Summit is very informative of people who are new to this field aswell as the ADC experts. All of the talks were excellent”.
Bristol- Myers Squibb, BDC

When we hosted the inaugural World ADC Summit in 2010, we were bowled-over by the magnitude of the conference - and with the vast range of companies actively involved with ADC development. Since then, the field has accelerated. Adcetris has received US marketing authorisation, and even more ADC candidates are achieving remarkable clinical success. The ADC field has truly come of age.

The World ADC Summit is the chosen platform for the leading companies including Genentech, ImmunoGen, Seattle Genetics, Pfizer, MedImmune & Celldex to reveal their latest news, discoveries and results.

Some highlights of the recent meeting included;

• Genmab, for the first time, spoke about its ADC candidates that use tissue factor as a novel target
• Roche’s Ulrich Brinkmann spoke about his revolutionary conjugated bispecific antibodies that bind haptens as well as cell surface antigens
• Attendees learned MedImmune’s approach to target selection
• Jonathan Drachman gave an update on his pipeline and the latest developments at Seattle Genetics
• Genentech’s Paul Polakis outlined his strategies to improve the therapeutic index of ADCs
• Genentech took us through mechanisms of resistance, pharmacokinetics considerations, and manufacturing and formulations challenges of ADCs
• ImmunoGen CSO John Lambert shared his criteria for creating the optimal ADC

Other companies that featured on the program: Pfizer, Takeda San Francisco, Celldex, Avipep, Lonza, SAFC, Baxter, Agensys, Quanta Biodesign, Synthon, Pieris, UCLA, Ambrx and the Weill Cornell Medical School.

Registration is now open for the World ADC Summit Europe (Frankfurt, 28 February - 1 March) and the World ADC Summit San Francisco (30th October - 1 November, 2012). For more information on the European meeting, please click here. 

To register for either meeting, simply email info@hansonwade.com or call us on +1 212 537 5898

Featured Speakers

• 

  Jonathan DrachmanSenior Vice President Seattle Genetics

• 

  Pamela TrailVice President Regeneron

• 

  David SatijnAssociate Director Genmab

• 

  John LambertExecutive Vice President & Chief Scientific Officer ImmunoGen

• 

  Paul PolakisDirector, Cancer Targets Genentech

• 

  Hans Peter GerberSenior Director, Bioconjugates and Vascular Biology Pfizer